The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Addressing treatment strategies for limited stage small cell lung cancer
Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, discusses treatment strategies for limited stage small cell lung cancer (SCLC). The THORA trial (NCT02041845) aimed to compare high dose with standard dose thoracic radiotherapy in limited stage SCLC. Even though many patients respond to the standard line of therapy of chemoradiotherapy, many also relapse. Hypothetically speaking, increasing radiotherapy doses may improve survival, but randomized trials have failed to show this. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
